AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
penciclovir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals bicyclic heterocycle compounds | 2079 | 39809-25-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The antiviral compound penciclovir has inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). In cells infected with HSV-1 or HSV-2, the viral thymidine kinase phosphorylates penciclovir to a monophosphate form that, in turn, is converted by cellular kinases to the active form penciclovir triphosphate. Biochemical studies demonstrate that penciclovir triphosphate inhibits HSV polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 170 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 75 % | Benet LZ, Broccatelli F, Oprea TI |
| BA (Bioavailability) | 77 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.10 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 8.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.84 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.10 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,CAMK2D,CDK5,DYRK1B,EIF2AK3,GRK2,ITK,MAP3K21,PDK1,PDK2,PRKDC | 11 | |||
| kinase-selectivity-class | AXL,CAMK2D,CDK1,CDK16,CDK2,CDK3,CDK4,CDK7,CDK9,CLK4,DYRK1A,MAP3K21,PDK1 | 13 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 24, 1996 | FDA | DENCO ASSET |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D06BB06 | DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE CHEMOTHERAPEUTICS FOR TOPICAL USE Antivirals |
| ATC | J05AB13 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Nucleosides and nucleotides excl. reverse transcriptase inhibitors |
| FDA MoA | N0000020060 | DNA Polymerase Inhibitors |
| FDA EXT | N0000175459 | Nucleoside Analog |
| FDA EPC | N0000175468 | Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| CHEBI has role | CHEBI:36044 | antiviral drug |
Related Drugs by ATC class:
D06BB Antivirals 11 drugs
J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors 11 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Herpes labialis | indication | 1475003 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.73 | acidic |
| pKa2 | 12.97 | acidic |
| pKa3 | 13.57 | acidic |
| pKa4 | 4.72 | Basic |
| pKa5 | 2.6 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| DNA polymerase catalytic subunit | Enzyme | INHIBITOR | DRUGBANK | CHEMBL | |||||
| Thymidine kinase | Kinase | IC50 | 4.96 | CHEMBL | |||||
| Thymidine kinase | Kinase | IC50 | 4.07 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020992 | VUID |
| N0000148462 | NUI |
| D02124 | KEGG_DRUG |
| 4020992 | VANDF |
| C0164815 | UMLSCUI |
| CHEBI:7956 | CHEBI |
| PE2 | PDB_CHEM_ID |
| CHEMBL1540 | ChEMBL_ID |
| DB00299 | DRUGBANK_ID |
| CHEMBL2079793 | ChEMBL_ID |
| C053539 | MESH_SUPPLEMENTAL_RECORD_UI |
| 135398748 | PUBCHEM_CID |
| 6437 | INN_ID |
| 97845-62-0 | SECONDARY_CAS_RN |
| 359HUE8FJC | UNII |
| 216450 | RXNORM |
| 363014 | MMSL |
| 5242 | MMSL |
| 6064 | MMSL |
| 006111 | NDDF |
| 108918003 | SNOMEDCT_US |
| 386939003 | SNOMEDCT_US |
| 359HUE8FJC | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Penciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3186 | CREAM | 10 mg | TOPICAL | ANDA | 25 sections |
| Penciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0896 | CREAM | 10 mg | TOPICAL | NDA authorized generic | 25 sections |
| Denavir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-9720 | CREAM | 10 mg | TOPICAL | NDA | 26 sections |
| Penciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-661 | CREAM | 10 mg | TOPICAL | ANDA | 26 sections |
| PENCICLOVIR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-440 | CREAM | 10 mg | TOPICAL | ANDA | 24 sections |
| Denavir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4956 | CREAM | 10 mg | TOPICAL | NDA | 20 sections |
| Penciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69238-1791 | CREAM | 10 mg | TOPICAL | ANDA | 25 sections |